Oxygen-Amplified Carrier-Free Nanomedicine Integrating Ferroptosis/Photodynamic Therapy and COX-2/PGE2 Blockade for Robust Antitumor Immunity Against Glioma.
Oct 2026· ACS Applied Materials and Interfaces· 0 citations· 46 references
Medicine
TL;DR
An oxygen‑amplified carrier‑free nanomedicine (IHC NPs) through hydrophobic self‑assembly of IR-820, hemin, and celecoxib is developed that provides a promising oxygen‑amplified carrier‑free nanomedicine for robust glioma immunotherapy.
Abstract
The therapeutic efficacy of glioma immunotherapy is severely hampered by immunosuppression in the tumor microenvironment. Here, we develop an oxygen‑amplified carrier‑free nanomedicine (IHC NPs) through hydrophobic self‑assembly of IR-820, hemin, and celecoxib. IHC NPs exhibit excellent stability, biological safety, and preferential tumor accumulation. In the subcutaneous glioma model, the combination of IHC NPs and αPD-L1 significantly inhibited subcutaneous tumor growth and effectively prevented distant tumor metastasis. Mechanistically, hemin catalyzes endogenous H2O2 to generate oxygen, thereby alleviating tumor hypoxia. This oxygen boost potentiates IR-820‑mediated photodynamic therapy and hemin-based ferroptosis, enhancing direct tumor cell killing. Concurrently, celecoxib blocks the COX‑2/PGE2 pathway, reversing immunosuppression within the tumor microenvironment. Through the synergistic strategy combining oxygen-sensitized photodynamic therapy, ferroptosis, COX-2/PGE2 suppression, and PD-1/PD-L1 blockade, this therapeutic regimen effectively induces tumor immunogenic cell death, promotes dendritic cell maturation, enhances intratumoral infiltration of cytotoxic T lymphocytes, reduces the abundance of regulatory T cells, and triggers the generation of effector memory T cells, thereby potently activating the host immune system. Collectively, our work provides a promising oxygen‑amplified carrier‑free nanomedicine for robust glioma immunotherapy.
This TME-responsive bimetallic nanoplatform successfully integrates radiosensitization, multimodal imaging, and PTT, offering a robust strategy for imaging-guided precision cancer therapy.
Rui-Ying Zhang, Miao-Qing Li, Rui Cao et al.· Journal of materials chemist...· 0 citations
Photodynamic therapy (PDT) holds great promise for cancer treatment owing to its spatiotemporal selectivity and minimal invasiveness. However, its therapeutic efficacy is hampered by photosensitizer self-quenching and intrinsic tumor hypoxia. Herein, we construct a tumor-microenvironment (TME)-activated dual-prodrug na...
Triple-negative breast cancer (TNBC) presents a serious therapeutic challenge, largely owing to its metabolic adaptability and the immunosuppressive nature of its tumor microenvironment (TME). Photodynamic therapy (PDT) can cause oxidative injury and induce immunogenic cell death (ICD); however, its antitumor activity...
Photodynamic therapy (PDT) can elicit antitumor immunity by inducing immunogenic cell death (ICD), making it an attractive option for postoperative local cancer treatment. However, in solid tumors, aberrant vasculature and an immunosuppressive microenvironment often restrict immune-cell infiltration, thereby weakening...